{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:19:20Z","timestamp":1782875960317,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40261-023-01322-2","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T18:02:10Z","timestamp":1701194530000},"page":"21-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects"],"prefix":"10.1007","volume":"44","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Philmore","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"1322_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185\u20138. https:\/\/doi.org\/10.1038\/13810.","journal-title":"Nat Genet"},{"key":"1322_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.braindev.2018.08.008","volume":"41","author":"CB Buchanan","year":"2019","unstructured":"Buchanan CB, Stallworth JL, Scott AE, Glaze DG, Lane JB, Skinner SA, et al. Behavioral profiles in Rett syndrome: data from the natural history study. Brain Dev. 2019;41:123\u201334. https:\/\/doi.org\/10.1016\/j.braindev.2018.08.008.","journal-title":"Brain Dev"},{"key":"1322_CR3","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1212\/WNL.0b013e3182377dd2","volume":"77","author":"JB Lane","year":"2011","unstructured":"Lane JB, Lee H-S, Smith LW, Cheng P, Percy AK, Glaze DG, et al. Clinical severity and quality of life in children and adolescents with Rett syndrome. Neurology. 2011;77:1812\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e3182377dd2.","journal-title":"Neurology"},{"key":"1322_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","volume":"278","author":"MJ Bickerdike","year":"2009","unstructured":"Bickerdike MJ, Thomas GB, Batchelor DC, Sirimanne ES, Leong W, Lin H, et al. NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J Neurol Sci. 2009;278:85\u201390. https:\/\/doi.org\/10.1016\/j.jns.2008.12.003.","journal-title":"J Neurol Sci"},{"key":"1322_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1358\/dof.2021.46.1.3208246","volume":"46","author":"BE Collins","year":"2021","unstructured":"Collins BE, Neul JL. Trofinetide. Glycine-proline-glutamate (GPE) analogue, treatment of Rett syndrome, treatment of fragile X syndrome. Drugs Fut. 2021;46:29. https:\/\/doi.org\/10.1358\/dof.2021.46.1.3208246.","journal-title":"Drugs Fut"},{"key":"1322_CR6","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","volume":"106","author":"D Tropea","year":"2009","unstructured":"Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009;106:2029\u201334. https:\/\/doi.org\/10.1073\/pnas.0812394106.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1322_CR7","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/wnl.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92:e1912\u201325. https:\/\/doi.org\/10.1212\/wnl.0000000000007316.","journal-title":"Neurology"},{"key":"1322_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","volume":"76","author":"DG Glaze","year":"2017","unstructured":"Glaze DG, Neul JL, Percy A, Feyma T, Beisang A, Yaroshinsky A, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37\u201346. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.07.002.","journal-title":"Pediatr Neurol"},{"key":"1322_CR9","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med. 2023;29:1468\u201375. https:\/\/doi.org\/10.1038\/s41591-023-02398-1.","journal-title":"Nat Med"},{"key":"1322_CR10","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.ejps.2017.05.032","volume":"109","author":"SP Oosterholt","year":"2017","unstructured":"Oosterholt SP, Horrigan J, Jones N, Glass L, Della PO. Population pharmacokinetics of NNZ-2566 in healthy subjects. Eur J Pharm Sci. 2017;109:S98\u2013107. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.032.","journal-title":"Eur J Pharm Sci"},{"key":"1322_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40261-022-01156-4","volume":"42","author":"M Darwish","year":"2022","unstructured":"Darwish M, Youakim JM, Harlick J, DeKarske D, Stankovic S. A phase 1, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects. Clin Drug Investig. 2022;42:513\u201324. https:\/\/doi.org\/10.1007\/s40261-022-01156-4.","journal-title":"Clin Drug Investig"},{"key":"1322_CR12","unstructured":"Darwish M, Passarell J, Maxwell K, Youakim JM, Bradley H, Bishop KM. Weight-based banded dosing to achieve target exposure and exposure-response efficacy analyses to support trofinetide treatment in Rett Syndrome [poster]. In: American Society for Clinical Pharmacology & Therapeutics (ASCPT) annual meeting, March 22\u201324, 2023, Atlanta, GA, USA."},{"key":"1322_CR13","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical method validation: guidance for industry. 2018. https:\/\/www.fda.gov\/media\/70858\/download. Accessed 5 June 2023."},{"key":"1322_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/clpt.1981.56","volume":"29","author":"RA Hamilton","year":"1981","unstructured":"Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther. 1981;29:408\u201313. https:\/\/doi.org\/10.1038\/clpt.1981.56.","journal-title":"Clin Pharmacol Ther"},{"key":"1322_CR15","unstructured":"Darwish M, Youakim JM, Darling I, Lukacova V, Owen JS, Bradley H, et al. Limited potential for interactions between trofinetide, an investigational agent for treatment of Rett syndrome, and antiseizure medications metabolized by CYP3A4 [poster]. In: 75th annual meeting of the American Epilepsy Society (AES), Dec 3\u20137, 2021: Chicago, IL, USA."},{"key":"1322_CR16","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/bcp.13961","volume":"85","author":"S Ma","year":"2019","unstructured":"Ma S, Suchomel J, Yanez E, Yost E, Liang X, Zhu R, et al. Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor. Br J Clin Pharmacol. 2019;85:1751\u201360. https:\/\/doi.org\/10.1111\/bcp.13961.","journal-title":"Br J Clin Pharmacol"},{"key":"1322_CR17","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1128\/aac.01750-09","volume":"54","author":"JP Shaw","year":"2010","unstructured":"Shaw JP, Cheong J, Goldberg MR, Kitt MM. Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother. 2010;54:3365\u201371. https:\/\/doi.org\/10.1128\/aac.01750-09.","journal-title":"Antimicrob Agents Chemother"},{"key":"1322_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cpdd.376","volume":"7","author":"R Townsend","year":"2018","unstructured":"Townsend R, Kato K, Hale C, Kowalski D, Lademacher C, Yamazaki T, et al. Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of 14C-labeled isavuconazonium sulfate in healthy male volunteers. Clin Pharmacol Drug Dev. 2018;7:207\u201316. https:\/\/doi.org\/10.1002\/cpdd.376.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1322_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","volume":"55","author":"KJ Motil","year":"2012","unstructured":"Motil KJ, Caeg E, Barrish JO, Geerts S, Lane JB, Percy AK, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr. 2012;55:292\u20138. https:\/\/doi.org\/10.1097\/MPG.0b013e31824b6159.","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01322-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:31:55Z","timestamp":1704457915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01322-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01322-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"26 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was sponsored by Acadia Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Acadia Pharmaceuticals Inc. is adhering to current US and EU requirements so will not make individual de-identified participant data available; however, the protocol and statistical analysis plan will be made available upon request to the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"MD, RN, and JMY are employees of Acadia Pharmaceuticals Inc. PR, Jr., is a consultant for Acadia Pharmaceuticals Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The trial was conducted in accordance with applicable regulations, including the current Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice. All requisite trial-related material, including the protocol, were reviewed by an institutional review board (IntegReview, approval number 4009273) and approved on May 4, 2020.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participating subjects provided written informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors made substantial contributions to the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}